First published in the Government Gazette, Electronic Edition, on 15 February 2019 at 5 pm.

No. S 97

MEDICINES ACT (CHAPTER 176)

MEDICINES (LICENSING, STANDARD PROVISIONS AND FEES) (AMENDMENT) REGULATIONS 2019

In exercise of the powers conferred by section 74 of the Medicines Act, the Minister for Health makes the following Regulations:

Citation and commencement

1. These Regulations are the Medicines (Licensing, Standard Provisions and Fees) (Amendment) Regulations 2019 and come into operation on 2 April 2019.

Deletion and substitution of Fifth Schedule

2. The Fifth Schedule to the Medicines (Licensing, Standard Provisions and Fees) Regulations (Rg 6) is deleted and the following Schedule substituted therefor:

"FIFTH SCHEDULE

Regulation 5

FEES

1. PRODUCT LICENCE

- (1) Application for a product licence for
 - (a) a medicinal product that has not yet been approved by any competent drug regulatory agency and is therefore required by the Authority to undergo full evaluation:
 - (i) application fee for the initial \$2,830 screening[#]
 - (ii) evaluation fee* \$82,700

S 97/2019

(b) a medicinal product that has been

approved by at least one competent drug regulatory agency and is therefore allowed by the Authority to undergo abridged evaluation:	
(i) application fee for the initial screening#	\$565
(ii) evaluation fee* for a single-strength product or the first product in a series of products of different strengths	\$11,200
(iii) evaluation fee* for each subsequent product in a series of products of different strengths	\$5,665
(c) a medicinal product that has been approved by a reference drug regulatory agency and is therefore allowed by the Authority to undergo verification evaluation:	
(i) application fee for the initial screening [#]	\$565
(ii) evaluation fee* for a single-strength product or the first product in a series of products of different strengths	\$16,700
(iii) evaluation fee* for each subsequent product in a series of products of different strengths	\$5,665
(2) Licence fee for —	
(a) the first year of the term of a product licence	Nil
(b) each subsequent year of the term of a product licence	\$309

(3) Application to amend	d a product licence	e —	
(a) to make a magaphication is a evaluation by the	required to under		
(i) application screening	on fee for the	initial	\$2,575
(ii) evaluatio	n fee*		\$51,200
	jor variation, wh n be reviewed gh abridged evalu	by the	
(i) application screening		initial	\$515
	ength product or to n a series of prod	the first	\$5,665
	n fee* for nt product in a so of different streng		\$2,830
• •	n be reviewed		
(i) application screening	on fee for the	initial	\$515
_	ength product or to n a series of prod	the first	\$8,450
_	n fee* for nt product in a so of different streng		\$2,830
(d) to make any product specific product:	other variations cations of a me		
(i) application	on fee#		\$565
(ii) evaluatio	n fee		Nil

2. IMPORT LICENCE (INCLUDING FOR CHINESE PROPRIETARY MEDICINES) \$515 (1) Application fee for an import licence (2) Licence fee for — Nil (a) the first year of the term of an import licence \$515 (b) each subsequent year of the term of an import licence (3) Application fee to amend an import licence — \$309 (a) with site inspection^ \$52 (b) without site inspection^ 3. WHOLESALE DEALER'S LICENCE (INCLUDING FOR CHINESE PROPRIETARY **MEDICINES**) \$515 (1) Application fee for a wholesale dealer's licence (2) Licence fee for — Nil (a) the first year of the term of a wholesale dealer's licence \$515 (b) each subsequent year of the term of a wholesale dealer's licence (3) Application fee to amend a wholesale dealer's licence — \$309 (a) with site inspection^ \$52 (b) without site inspection^ 4. MANUFACTURER'S LICENCE (INCLUDING FOR CHINESE PROPRIETARY MEDICINES) (1) Application fee for a manufacturer's licence for — \$1,545 (a) manufacture of external preparations only \$1,545 (b) manufacture of oral preparations only \$2,060 (c) manufacture of external and oral preparations only

(d) manufacture of sterile pother types of dosage for form combinations not sub-paragraphs (a), (b) medicinal product is proprietary medicine	orms or dosage described in and (c) , if the
(e) primary assembly of a me	edicinal product \$1,030
(f) secondary assembly of product	f a medicinal \$615
(2) Licence fee for —	
(a) the first year of the manufacturer's licence	e term of a Nil
(b) each subsequent year of manufacturer's licence for	
(i) manufacture or preparations only	of external \$1,545
(ii) manufacture of or only	ral preparations \$1,545
(iii) manufacture of ex preparations only	ternal and oral \$2,060
(iv) manufacture preparations, or of dosage forms or combinations not sub-paragraphs (i), the medicinal pro Chinese proprietary	dosage form described in (ii) and (iii), if oduct is not a
(v) primary assembly product	of a medicinal \$1,030
(vi) secondary assembly product	y of a medicinal \$615

(3) Application fee to amend a manufacturer's licence —	
(a) with site inspection (for a licence to manufacture a medicinal product)	\$1,030
(b) with site inspection (for a licence to assemble a medicinal product)	\$515
(c) without site inspection^	\$52
5. CERTIFICATES AND DOCUMENTS (NON-MANDATORY)	
(1) Application fee for a Certificate to Export a Medicinal Product	\$103
(2) Application fee for a Certificate to Export a Chinese Proprietary Medicine	\$103
(3) Application fee for a Confirmation of Authorisation to Import a Psychotropic Substance	\$103
(4) Application fee for a Confirmation of Authorisation to Import a Restricted Substance	\$103

[#] Fee is payable upon submission of application.

[G.N. Nos. S 309/2001; S 641/2002; S 621/2003; S 384/2004; S 416/2005; S 499/2005; S 558/2005; S 681/2005; S 821/2005; S 648/2006; S 28/2007; S 510/2010; S 693/2010; S 547/2016]

^{*} Fee is payable upon acceptance of application.

 $^{^{\}wedge}$ Refer to the Authority's guidance notes on amendment applications for licences (available at the Authority's website) to find out if a site inspection is required. ",

Made on 8 February 2019.

CHAN HENG KEE Permanent Secretary, Ministry of Health, Singapore.

[HSA/Legal/2019:05; AG/LEGIS/SL/176/2015/9 Vol. 1]